TWA
RXRX icon

TCI Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

TCI Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-594
Closed -$4K – 2482
2022
Q1 		$4K Buy
594
+379
+176% +$4.03K ﹤0.01% 1777
2021
Q4 		$4K Buy
+215
New +$4.04K ﹤0.01% 1887

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCI Wealth Advisors's RXRX Position: Q2 2022 in Review

TCI Wealth Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 594 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in RXRX in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

  • TCI Wealth Advisors reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • TCI Wealth Advisors sold 594 Recursion Pharmaceuticals shares in Q2 2022, an estimated $4K.
  • TCI Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • TCI Wealth Advisors's Recursion Pharmaceuticals position peaked at $4K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on TCI Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.